News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
393,840 Results
Type
Article (26329)
Company Profile (60)
Press Release (367449)
Multimedia
Podcasts (34)
Webinars (7)
Section
Business (104393)
Career Advice (455)
Deals (16890)
Drug Delivery (53)
Drug Development (47741)
Employer Resources (47)
FDA (12346)
Job Trends (8483)
News (186359)
Policy (19522)
Tag
2027 Biotech Bay Standard (1)
2027 Pharm Country Standard (1)
Academia (1757)
Accelerated approval (14)
Adcomms (10)
Allergies (110)
Alliances (26825)
ALS (95)
Alzheimer's disease (972)
Antibody-drug conjugate (ADC) (161)
Approvals (12679)
Artificial intelligence (302)
Autoimmune disease (89)
Automation (8)
Bankruptcy (142)
Best Places to Work (6892)
BIOSECURE Act (5)
Biosimilars (73)
Biotechnology (40)
Bladder cancer (124)
Brain cancer (36)
Breast cancer (415)
Cancer (3060)
Cardiovascular disease (265)
Career advice (416)
Career pathing (15)
CAR-T (133)
CDC (26)
Celiac Disease (2)
Cell therapy (363)
Cervical cancer (26)
Clinical research (42938)
Collaboration (849)
Compensation (271)
Complete response letters (16)
COVID-19 (1553)
CRISPR (35)
C-suite (484)
Cystic fibrosis (59)
Data (4221)
Decentralized trials (2)
Denatured (20)
Depression (93)
Diabetes (316)
Diagnostics (3712)
Digital health (28)
Diversity (7)
Diversity, equity & inclusion (13)
Drug discovery (94)
Drug pricing (91)
Drug shortages (22)
Duchenne muscular dystrophy (123)
Earnings (38626)
Editorial (28)
Employer branding (6)
Employer resources (46)
Events (54210)
Executive appointments (584)
FDA (14619)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (5)
Frontotemporal dementia (10)
Funding (750)
Gene editing (75)
Generative AI (20)
Gene therapy (258)
GLP-1 (542)
Government (3142)
Grass and pollen (4)
Guidances (229)
Healthcare (12211)
HIV (38)
Huntington's disease (20)
IgA nephropathy (50)
Immunology and inflammation (81)
Immuno-oncology (25)
Indications (67)
Infectious disease (1684)
Inflammatory bowel disease (109)
Inflation Reduction Act (7)
Influenza (51)
Intellectual property (118)
Interviews (40)
IPO (7072)
IRA (23)
Job creations (1845)
Job search strategy (381)
JPM (18)
Kidney cancer (10)
Labor market (34)
Layoffs (194)
Leadership (8)
Legal (3646)
Liver cancer (66)
Longevity (7)
Lung cancer (481)
Lymphoma (249)
Machine learning (16)
Management (17)
Manufacturing (288)
MASH (105)
Medical device (13298)
Medtech (13343)
Mergers & acquisitions (10329)
Metabolic disorders (750)
Multiple sclerosis (96)
NASH (11)
Neurodegenerative disease (160)
Neuropsychiatric disorders (42)
Neuroscience (1687)
NextGen: Class of 2026 (3933)
Non-profit (2838)
Now hiring (33)
Obesity (310)
Opinion (95)
Ovarian cancer (119)
Pain (140)
Pancreatic cancer (140)
Parkinson's disease (164)
Partnered (17)
Patents (224)
Patient recruitment (349)
Peanut (42)
People (35639)
Pharmaceutical (15)
Pharmacy benefit managers (16)
Phase 1 (12340)
Phase 2 (18571)
Phase 3 (15266)
Pipeline (3024)
Policy (125)
Postmarket research (1668)
Preclinical (3797)
Press Release (18)
Prostate cancer (177)
Psychedelics (26)
Radiopharmaceuticals (177)
Rare diseases (425)
Real estate (2870)
Recruiting (18)
Regulatory (15680)
Reports (18)
Research institute (1653)
Resumes & cover letters (49)
Rett syndrome (16)
RNA editing (5)
RSV (39)
Schizophrenia (113)
Series A (116)
Series B (93)
Service/supplier (2)
Sickle cell disease (45)
Special edition (6)
Spinal muscular atrophy (104)
Sponsored (17)
Startups (2134)
Stomach cancer (11)
Supply chain (60)
Tariffs (25)
The Weekly (14)
Vaccines (502)
Venture capital (27)
Weight loss (209)
Women's health (54)
Worklife (4)
Date
Last 7 days (303)
Last 30 days (1059)
Last 365 days (16124)
2026 (1471)
2025 (16470)
2024 (19848)
2023 (22753)
2022 (30685)
2021 (32991)
2020 (32196)
2019 (28422)
2018 (21814)
2017 (18913)
2016 (18117)
2015 (21195)
2014 (16024)
2013 (13241)
2012 (14350)
2011 (14627)
2010 (13181)
Location
Africa (367)
Alabama (30)
Alaska (2)
Arizona (174)
Arkansas (10)
Asia (25486)
Australia (4029)
California (5566)
Canada (1903)
China (782)
Colorado (285)
Connecticut (285)
Delaware (249)
Europe (49874)
Florida (949)
Georgia (225)
Hawaii (1)
Idaho (35)
Illinois (577)
India (32)
Indiana (376)
Iowa (11)
Japan (314)
Kansas (90)
Kentucky (19)
Louisiana (18)
Maine (28)
Maryland (890)
Massachusetts (3734)
Michigan (149)
Minnesota (442)
Mississippi (5)
Missouri (78)
Montana (19)
Nebraska (21)
Nevada (65)
New Hampshire (73)
New Jersey (1921)
New Mexico (10)
New York (1563)
North Carolina (810)
North Dakota (4)
Northern California (2643)
Ohio (212)
Oklahoma (8)
Oregon (28)
Pennsylvania (1347)
Puerto Rico (11)
Rhode Island (35)
South America (523)
South Carolina (59)
Southern California (2234)
Tennessee (124)
Texas (1017)
United States (21592)
Utah (194)
Virginia (141)
Washington D.C. (52)
Washington State (384)
West Virginia (4)
Wisconsin (71)
Wyoming (1)
393,840 Results for "monarch medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
NeuroSigma Completes $1 Million Investment into High-Volume Manufacturing Line for Second Generation Monarch eTNS® Device
December 16, 2025
·
3 min read
Policy
MONARCH Platform for Bronchoscopy Receives Regulatory License for China
Johnson & Johnson MedTech* announced that the MONARCH Platform and MONARCH Bronchoscope have obtained regulatory approval in China.
November 13, 2023
·
5 min read
Press Releases
Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
May 29, 2025
·
4 min read
Biotech Beach
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products.
October 3, 2023
·
2 min read
Biotech Beach
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation Monarch eTNS System™ (Monarch 2.0).
November 7, 2023
·
1 min read
Business
Semler Announces Investment in Monarch Medical Technologies
Semler Scientific, Inc. today announced an up to $5.0 million investment in privately-held Monarch Medical Technologies, LLC (Monarch) through the purchase of a senior secured convertible promissory note. Repayment of the note is secured by a first priority interest in all of Monarch’s assets.
December 12, 2022
·
5 min read
Policy
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
NeuroSigma announced that the U.S. Food and Drug Administration cleared use of NeuroSigma’s second-generation Monarch eTNS System for treating pediatric attention deficit hyperactivity disorder.
January 18, 2024
·
2 min read
Drug Development
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it has initiated MONARCH, a Phase 2b trial of its proprietary selective cortisol modulator miricorilant in patients with non-alcoholic steatohepatitis (NASH).
October 26, 2023
·
3 min read
Press Releases
Medical-imaging company Imagion Biosystems Lodges IND with FDA for Phase 2 Trial of MagSense® HER2 targeted imaging agent
February 4, 2026
·
2 min read
Job Trends
Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS).
December 5, 2023
·
28 min read
1 of 39,384
Next
